今天是:
当前位置: 首页 » 专题 » 第三届中医科学大会 » 专家库

第三届中医科学大会参会院士及国医大师简历

来源:农工党中央宣传部  时间:2016-08-23 02:47:00  编辑:胡文生

陈竺


 
陈竺,中国科学院院士,发展中国家科学院院士,美国科学院和美国医学科学院外籍院士,英国皇家学会外籍会员,欧洲艺术、科学和人文学院外籍院士,欧洲科学院外籍院士,法国科学院外籍院士,香港医学专科学院荣誉院士,英国医学科学院荣誉院士,德国马普学会分子遗传研究所外籍会员。现任全国人大常委会副委员长,农工党中央主席,欧美同学会•中国留学人员联谊会会长,中国红十字会会长,上海血液学研究所名誉所长,上海交通大学系统生物医学研究院院长。
陈竺教授在在血液学、分子生物学领域取得了很多突破性成果,从分子水平上揭示了维甲酸治疗早幼粒白血病的原理,在世界上首次阐明三氧化二砷(砒霜)治疗白血病的分子机理,取得了急性早幼粒细胞白血病基本治愈、多种人类疾病相关基因发现、多个病原体基因组解析等重大成果。参与我国人类基因组研究计划的运筹、组织和管理,建立了初具规模的人类基因组研究技术体系,组建了我国首个国家级基因组研究中心——国家人类基因组南方研究中心。是“973”计划首批项目的首席科学家,曾任国家“863”计划十一·五期间生物领域首席科学家。在国际著名刊物如《Nature》、《Science》、《Nature Genetics》、《Blood》、《PNAS》和《Leukemia》等发表论文300多篇,引证数达21000余次。获得国家自然科学二等奖、国家科技进步二等奖、上海市科技进步一等奖、何梁何利基金科学技术奖、长江学者成就奖一等奖和法国全国抗癌联盟卢瓦兹奖、全美癌症研究基金会圣捷尔吉癌症研究创新成就奖等多个国内外重大奖项。
 


王琦

 
王琦,男,19432月生,江苏高邮人,国医大师1980年毕业于中国中医科学院(原中医研究院)获得硕士学位。1980年至1994年任中国中医科学院研究生部副主任,1994年至2001年任中国中医药报社副总编。现任北京中医药大学终身教授、主任医师、研究员、博士生导师,中央保健委员会会诊专家,国际欧亚科学院院士。中华中医药学会中医体质分会主任委员,世界中医药学会联合会体质研究专业委员会会长。第二、三、四批全国老中医药专家学术经验继承指导老师,中医药传承博士后合作导师。国家重点基础研究发展计划(“973”计划)首席科学家,享受国务院特殊津贴的有突出贡献专家。2013年获全国优秀科技工作者称号、首都劳动奖章、何梁何利基金科技进步奖,2014年获中华中医药学会终身成就奖。
王琦先后主持国家级科研项目11项(包括“973”项目2项,国家自然科学基金重点项目1项),获得国家科技进步二等奖1项,部级一等奖8项,二等奖6项,发明专利6项。主编专著67部,发表论文400余篇,SCI收录15篇。他先后培养学术继承人7名,博士后10名,博士、硕士88名,各省市研修人才数十名。
 


吕景山

吕景山,国医大师。山西省政协七届委员会委员,中国针灸学会第三届理事会理事、中国针灸学会腧穴分会副理事长,第三、四批全国老中医药专家学术经验继承工作指导老师。1992年获国务院颁发的政府特殊津贴。2010年被评为首届“山西名医”。2014年获得第二届“国医大师”荣誉称号,中华中医药学会“终身成就奖”,2014“感动山西”特别奖。他先后培养了包括加拿大、香港等地在内的弟子五十余人。在学术上他师古不泥,独辟蹊径,形成对药理论、对穴理论和对法理论。对药理论填补了迄今一千四百多年以来药对配伍专辑的空白。对穴理论为针灸学和针灸处方学的研究和发展创新了思路。出版论著十余部,其中《施今墨对药》和《吕景山对穴临床经验集》,被译为日文、韩文等多个版本,获得1982年度全国优秀科技图书一等奖,山西省1983年科技成果二等奖。

20151218日,在惠州市中医医院设立了广东省首间“吕景山国医大师传承工作室”,引进吕老及其弟子团队,定期来惠开展带教、查房、授课及特色诊疗,并在该院逐级推荐的候选人中择优选拔4名拔尖人才收为吕老的师承弟子,承担吕景山学术思想和临床经验的总结、传承任务,使其“对药”、“对穴”学术精髓、学术理论和临床经验得以根植和传承,使其独到的临床疗效惠及惠州百姓。





陈国强
 


 
陈国强,医学博士、中国科学院院士,现任上海交通大学医学院院长,上海交通大学副校长,细胞分化与凋亡教育部重点实验室主任。他长期从事肿瘤尤其是白血病细胞命运决定和肿瘤微环境调控机制研究,报道低氧通过低氧诱导因子-1HIF-1)的非转录功能,诱导白血病细胞分化,并揭示了Cbx4类泛素化修饰HIF-1a,调控肿瘤新生血管生成与转移;报道白血病干/祖细胞诱导骨髓间充质细胞分化形成新的骨髓微环境和该微环境保护白血病细胞的机制;发现天然产物腺花素通过靶向过氧化物还原酶家族成员,诱导白血病细胞分化等,在国际重要核心刊物如Cancer Cell, Nature Chemical Biology, Blood等发表130余篇学术论文, 被他引5000余次,曾获国家自然科学二等奖、中华医学科技一等奖、上海市自然科学一等奖、何梁何利科学与技术进步奖等。

       Guo-Qiang Chen, M.D., Ph.D, academician of Chinese Academy of Science, President of Shanghai Jiao Tong University School of Medicine, vice president of Shanghai Jiao Tong University, and director of key Lab. Cell Differentiation and Apoptosis of Ministry of Education of China. He has been devoting his efforts to investigate the mechanisms of cell fate determination of cancer cells, especially acute myeloid leukemic cells, and effects of microenvironment on cancer cells, and made a series of original and more attractive discoveries through more than 120 of peer-reviewing publications in the international journals such as Cancer Cell, Nature Chemical Biology, Blood, and so on. For instances, he identified the first natural compound adenanthin to target peroxiredoxin I/II against leukemia by differentiation induction; reported hypoxia-hypoxia-inducible factor-1 (HIF-1a)- C/EBPa/Runx1 signaling in differentiation induction of AML cells, and Cbx4 enhancing hypoxia-induced VEGF expression and angiogenesis in hepatocellular carcinoma cells through sumoylating HIF-1α. Also, he identified a therapy-induced niche that protects leukemia-propagating cells.




陈凯先
  
陈凯中国科学院院士,上海巿科协主席,上海中医药大学教授、学术委员会主任,中国科学院上海药物研究所研究员、学位委员会主任。曾任中科院上海药物所所长,上海中医药大学校长,中国中西医结合学会会长。现任国家重大科技专项《重大新药创制》技术副总师,中医973专项专家顾问组副组长,国际标准化组织中医药标准技术委员会(ISO/TC249)主席顾问,中国药学会副理事长,中华中医药学会副会长。
多年来,陈凯致力于药物构效关系和新药发现研究。近十余年来参加组织、实施和承担了一批中医973计划和支撑计划项目,为推动中医药现代化、国际化做出了贡献。在国内外重要学术刊物上发表学术论文230多篇,获专利授权16项。曾获上海市科技精英、863计划突出贡献先进个人、何梁何利科技进步奖等多项国内外荣誉称号和科技奖励。
 
He is an academician of the Chinese Academy of Sciences (CAS), professor and director of the Academic Committee at Shanghai University of TCM, researcher and director of the Degree Committee at Shanghai Institute of Materia Medica.
He was the Director of Shanghai Institute of Materia MedicaChinese Academy of Sciences, the president of Shanghai University of Traditional Chinese Medicine. He is now the Chairman of Shanghai Association of Science and Technology, the deputy chief expert of the national key project Significant New Drug Development, deputy director of the consultant group at TCM 973 Initiative, consultant to the Chairman of ISO/TC249, deputy chairman of the Chinese Pharmaceutical Association and China Association of Chinese Medicine.
He has always been committed to researching on structure-activity relationship and new drug discovery. He contributed to the development and improvement of technologies and methods for drug design in multiple aspects. He delved into the research on drug design and new drug discovery, and applied them to the computational mining of TCM effective components and TCM evidence-based research. He used to be one of the chief experts in charge of the project of Innovative Drug and TCM Modernization duringthe period of the 9th 5-year plan and 10th 5-year plan. Over the past decade, he has organized and undertaken a series of TCM 973 Initiatives, which promoted the inter-disciplinary cooperation and integration of modern pharmacology, TCM, life science, and information science, contributing to new drug R&D in China, as well as the modernization and globalization of TCM.
Dr. Kaixian Chen




陈赛娟
 
陈赛娟,中国工程院院士,发展中国家科学院院士,法国医学科学院外籍院士,英国皇家内科医师学院院士,上海交通大学医学院附属瑞金医院上海血液学研究所研究员、所长,医学基因组学国家重点实验室主任,国家转化医学研究中心(上海)主任,中华医学会副会长,中国病理生理学会实验血液学专业委员会主任委员,中国青少年科技辅导员协会理事长,中国女科技工作者协会副会长,上海医学会副会长,十届、十一届全国人大代表,十二届全国政协委员
 
长期致力于白血病发病机理与治疗研究。率先提出并实施了白血病基因组解剖学计划,发现了一批新的白血病发病相关的突变基因与融合基因,揭示了白血病发病的新机制,为临床诊断、预后判断和靶向治疗提供了新的生物分子标志和靶标,并建立了急性髓性白血病(AML)预后相关的分子分型体系,进一步完善和丰富了白血病发病的分子机理,为制定分子靶向治疗策略提供了理论依据。以AML中的两个亚型急性早幼粒细胞白血病(APL)和AML-M2b为研究对象,成功地实现了APL 新型协同靶向治疗,并进一步将这一思路拓展至其他类型白血病。她领导的研究团队在包括Nature Genetics ScienceDevelopment CellNature Commun.Blood PNAS在内的国际高水平期刊发表论文300多篇,被引证数达20000余次。获得国家自然科学二等奖、上海市自然科学奖特等奖等国家和省部级科技奖10余项。





 

陈香美
 
陈香美,中国工程院院士,中国人民解放军总医院主任医师、教授、博士生导师,全军肾脏病研究所所长,肾脏疾病国家重点实验室主任。国家慢性肾病临床医学研究中心主任,国家肾脏疾病质量控制中心主任,中华医学会常务理事,中华肾脏病学会第七、八届主任委员,中国中西医结合学会会长兼肾脏疾病专业委员会主任委员、中国医师协会肾脏内科医师分会会长。主要研究领域为IgA肾病、糖尿病肾病、老年相关肾损害、重症急性肾损伤以及全国血液净化数据登记和医疗质量控制。发表SCI论文180余篇。主编著作10部。以第一完成人获国家科学技术进步创新团队奖1项,国家科学技术进步奖二等奖4项、中国中西医结合学会科学技术一等奖1项、北京市科学技术一等奖2项、中华医学科技一等奖3项、中国人民解放军科学技术进步一等奖1项。
 
 
Chen Xiangmei, Academician of Chinese Academy of EngineeringChief Physician, Professor, Doctoral Tutor, Director of Chinese PLA Institute of Nephrology, Director of State Key Laboratory of Kidney DiseasesDirector of National Clinical Research Center for Kidney DiseasesDirector of National Medical Quality Control Center for Kidney Diseases, Executive Director of the Chinese Medical Association, President of the 7th and 8th Chinese Society of Nephrology, President of the Chinese Society of Integrative Medicine, President of the Chinese Nephrologist Association. The main research areas consist of IgA nephropathy, diabetic nephropathy, age-related kidney diseases, acute kidney injury, and nationwide blood purification data registry and medical quality control. She published more than 180 papers in SCI-index journals. To date she has edited ten books. She won a National Science and Technology Progress Award and the Innovation Team Award, and also won FOUR National Prizes of Second Grade for Advancements in Science and Technology, ONE Chinese Society of Integrative Medicine Prizes of First Grade for of Science and Technology, TWO Beijing Municipal Science and Technology Commission Prizes of First Grade for Science and Technology, THREE Chinese Medical Association Prizes of First Grade for of Science and Technology, ONE PLA Prize of First Grade for Advancements in Science and Technology. 




程京
 
程京 博士
清华大学医学院长江学者计划特聘教授,生物芯片北京国家工程研究中心主任,中组部千人计划入选者,中国工程院院士,国际欧亚科学院院士。
1992年在英国史查克莱大学纯粹及应用化学系获司法生物学博士学位。从事基础医学和临床医学相关生物技术研究,在生物芯片的研究中有重要建树和创新。站在国际生物芯片研究前沿并结合国情,主持建立了国内急需的疾病预防、诊断和预后分子分型芯片技术体系,领导研制了基因、蛋白和细胞分析所需的多种生物芯片,其中一批芯片已通过国家食品药品监督管理局认证、进入临床应用,实现了生物芯片所需全线配套仪器的国产化。
在英文学术刊物上发表论文130余篇,出版中英文专著8部,获国际发明专利105项、中国发明专利115项。曾荣获国家技术发明奖二等奖等。
 
Jing Cheng, Ph.D.
Cheung Kong Professor at Tsinghua University School of Medicine, Director of National Engineering Research Center for Beijing Biochip Technology, Member of the Chinese Academy of EngineeringMember of the InternationaI Academy of Sciences for Europe and Asia and National “Thousand Talents” Distinguished Professor.
Dr. Cheng received his Ph.D. degree in Forensic Sciences from the University of Strathclyde (UK) in 1992. He has been engaged and made great achievements in biotechnology researches related to both basic and clinical medicine, especially in the field of biochip technology. He has established series of biochip-based molecular typing systems for disease prevention, diagnosis and prognosis; and developed a variety of biochips for the analysis of genes, proteins and cells. Some of these chips have been certified by the Chinese Food and Drug Administration and applied in the hospital. Additionally, he has been responsible in developing and manufacturing a full line of instruments for biochips.
Dr. Cheng published more than 130 peer-reviewed papers, edited 8 books, obtained 115 national patent105 European and US patents. He received many awards including the Second Prize of the National Awards for Technological Innovation.



                                      
                                                     黄璐琦 
                                                                                                        
 
黄璐琦,中国工程院院士。北京大学医学部博士,现任中国中医科学院常务副院长、首席研究员,中药资源中心主任,全国中药资源普查试点工作专家指导组组长,科技部重点领域中药资源创新团队负责人,部局共建道地药材国家重点实验室(培育基地)负责人,曾任国家973计划项目首席科学家。组织实施第四次全国中药资源普查试点工作,提出和发展了“分子生药学”和道地药材形成的理论,建立了珍稀濒危常用中药资源五种保护模式。获国家科学技术进步二等奖4项(第一完成人3项,第二完成人1项)。获国家杰出青年科学基金资助、全国优秀博士学位论文指导教师等荣誉。
 
Huang Luqi, academician of Chinese Academy of Engineering, PHD from Peking University health science centre, vice-president of China academy of Chinese Medical Sciences, leading researcher, director of National Resource Center for Chinese MateriaMedica, group leader of the experts guiding group for the national survey on Chinese Medicinal Material Resources, head of Chinese Medicinal Material Resources innovation team of key area issued by Ministry of science and technology, director of State key laboratory of Dao-di Herbs that was established by both Ministry of science and technology and State administration of traditional Chinese medicine, former national 973 plan project chief scientist. Carried out the 4th national survey on Chinese Medicinal Material Resources. Put forward and developed the theories of “Molecular Pharmacognosy” and Dao-di Herbs formation. Established 5 protection modes on rare and endangered TCM resources which are commonly used. Won the second prize of state science and technology progress award 4 times (3 times as the first completed person and once as the second completed person). He is the winner of "National outstanding youth fund ", "the award for supervisor of the national outstanding doctoral dissertations" and so on.




宁光
 
宁光教授是中国工程院院士、中国医师协会内分泌代谢科医师分会会长、中华医学会内分泌学分会前任主任委员和《中华内分泌代谢杂志》总编辑,是国家杰出青年科学基金获得者、教育部长江学者特聘教授、973项目首席科学家、国际内分泌学会执委会委员。
宁光教授长期从事内分泌代谢病临床与科研工作,尤其在内分泌肿瘤与糖尿病诊治及研究领域成果丰硕, 包括临床证实小檗碱具降低体重和改善糖脂代谢作用,并发现白色脂肪棕色化是机制之一。在ScienceJAMANat Cell BiolJACCNat GenetSCI杂志发表论文250余篇,获国家科技进步二等奖3项(2项排名第一,1项第二)及上海市科技进步一等奖3项(排名第一)。宁光教授获评2014年度中国医师奖、吴阶平医药创新奖、美国内分泌医师协会International Endocrinologist Award及以色列糖尿病学会与以色列卫生部共同授予的Lifetime Award in Diabetes,并带领瑞金内分泌代谢学科成为国家重点学科、国家代谢性疾病临床医学研究中心、基金委创新群体、国家卫计委临床重点专科及《中国最佳专科声誉排行榜》连续五年排名第一,为推动我国内分泌代谢病事业的发展及提升国际地位做出了积极贡献。
 
Guang Ning is the academicians of Chinese Academy of Engineering, Chair of Chinese Society for Clinical Endocrinologists, Chief Editor of the Journal of Chinese Endocrinology. He is receiver of the National Science Fund for Distinguished Young Scholars, “Changjiang” Professor, "973" project chief scientist. He is also member of the Executive committee of International Endocrine Society.
He has been working in the field of endocrine & metabolic diseases for years and mainly achieved in endocrine tumor and diabetes. Two of his findings are related with Berberine: Berberine is effective and safe in the treatment of type 2 diabetes and dyslipidemia; Berberine activates thermogenesis in white and brown adipose tissue. He has been supported by more than 20 grants, including Sector Funds of Ministry of Health, the National Key Technology R&D Program, NSFC innovation research group and the National Basic Research Program (973 Program). He has published 250 papers in peer-reviewed journals, including ScienceJAMANat GenetNat Cell BiolJ Am Coll Cardiol and. He was winner of the National Science and Technical Progress Awards (2nd class) in 2008, 2010 and 2012 respectively (two rank first place and one rank second place). He was winner of Chinese Physician Award, Wu Jieping Medicine Innovation Prize, International Endocrinology Award from American Association of Clinical Endocrinologists, Lifetime Achievement Award from Israel Diabetes Association and Ministry of Health.




吴以岭
 
吴以岭院士简介
吴以岭,男,194910月出生,中国工程院院士,著名中医心血管病专家,中医络病学学科创立者和学科带头人,教授、博士生导师,两项国家973计划项目首席科学家,络病研究与创新中药国家重点实验室主任,国家心血管病中心专家委员会副主任委员、国家中医药管理局络病重点研究室主任,兼任中国中西医结合学会副会长、中华中医药学会副会长、中华中医药学会络病分会主任委员。
继承创新首次形成“络病证治”体系和“脉络学说”,创立中医络病学新学科,以络病理论为指导开辟心血管疾病治疗新途径。以第一完成人获国家科技发明二等奖1项、国家科技进步二等奖3项、省部级一等奖5项及何梁何利奖。主编《络病学》、《脉络论》等专著,其中《络病学》专著获中华中医药学会学术著作一等奖,主编新世纪全国高等中医药院校创新教材——《络病学》在40余家高等医学院校开课,建立三大络病专业委员会及28省市络病专委会。创立“理论-临床-新药”一体化发展模式,对推动中医药学术发展与现代化做出贡献。
 
About Academician Wu Yi-ling
Professional Distinctions
Male, Birth in Oct 1949
Academician, Chinese Academy of Engineering
Famous Traditional Medicine expert, cardiovascular diseases
Founder, Discipline of Collateral Disease Theory in Practice
Professor and doctoral tutor
Chief scientist for two national natural science foundation projects (973)
Head, State Key Laboratory of Collateral Disease Research and Innovation Medicine
Vice chairman, National Cardiovascular Center Expert Committee
Head, Key Laboratory of Collateral Diseases, State Administration of Traditional Chinese Medicine
Professional Affiliations
Vice chairman, Chinese Association of the Integration of Traditional and Western Medicine
Vice chairman, China Association of Chinese Medicine
Director, Collateral Disease Branch, China Association of Chinese Medicine
 
Academic influence and Awards
He inherited and innovated collateral disease theory system and Vessel-Collateral Theory for the first time., as a new subject in traditional Chinese medicine. Bases on collateral disease theory, Professor Wu developed new treatment for cardio-cerebrovascular disease. As first executer,one projects won second prize of State science and technology invention award, three projects won the second prize of national science and technology progress award and five projects won the first prize of provincial-level incentives. He edited collateral disease theory in practice and channel meridian theory. The book of collateral disease theory in practiceobtained the first prize of academic works of China association of Chinese medicine. The textbook of collateral disease theory in practicehas been widely used in 40 medical colleges. Professor Wu set up collateral disease committee of China Association of Chinese Medicine and collateral disease special committee in 28 provinces &cities. He created “theory-clinic-new drug” integrative development pattern and promoted the development and modernization of traditional Chinese medicine academy.




张伯礼
  
张伯礼,教授、博士生导师,中国工程院院士,现任中国中医科学院院长,天津中医药大学校长。国家重大新药创制科技重大专项技术副总师,国务院医改咨询专家委员会委员。国家重点学科中医内科学带头人,中国中西医结合学会名誉会长、中华医学会副会长、中华中医药学会副会长,教育部中医学类教育指导委员会主任委员,世界中医药学会联合会中医教育指导委员会主任委员。
致力于心脑血管疾病防治和中药现代化研究。开展血管性痴呆(VD)系统研究,制定了VD证类分型标准和按平台、波动及下滑三期证治方案;明确了中风病中医证候和先兆症动态演变规律,建立了综合治疗方案;创立了脑脊液药理学方法,研究中药对神经细胞保护的作用机制;连续承担三项“973”计划项目,开创了以组分配伍研制现代中药的新途径;完成了首个中药对冠心病二级预防的大规模临床研究,建立了中医药循证评价系列方法和关键技术;开拓名优中成药二次开发领域,培育了大品种群,推动了中药产业技术升级。
获国家科技奖励7项,一等奖1项,省部级科技进步一、二等奖20余项,发表论文200余篇,培养出站博士后、毕业博、硕士研究生180余名。
      
Zhang Boli, Professor, doctoral supervisor, academician of Chinese Academy of Engineering, President of the China Academy of Chinese Medical Sciences and President of the Tianjin University of Traditional Chinese Medicine. He isTechnological Vice chiefengineer of the National Major Scientific and Technological Special Project for “Significant New Drugs Development”, Member of the Consulting Expert Committee on Healthcare System Reform of the State Council, the academic leader of internal medicineof TCM, Honorary President of the China Association of Integrative Medicine, Vice President of Chinese Medical Association, Vice President of the China Association of Traditional Chinese Medicine, Director of the National Chinese Medicine Teaching Advisory Board of the Ministry of Education, Director of the Educational Instruction Committee of World Federation of Chinese Medicine Societies.
He mainly devoted to the research of preventing and treating cardiovascular and cerebrovascular diseases and the modernization of TCM.He completed systematic researches on vascular dementia (VD) and formulated the classification standard of VD symptoms and a treatment scheme for three-phase of VD, including platform, fluctuatingand gliding phase. He specified the TCM symptomsof stroke and dynamic evolution of premonitory symptoms, and developed comprehensive therapeutic schedule.He developed pharmacological method of cerebrospinal fluid (CSF) and the illustrated the protection mechanism of Chinese material medica for neurocyte. He has continuously hold three national basic research program of China (973 program) and developed the new method to R&D of the modern Chinese drugs with component-basedcompatibility.
He has completed the first lager scalerandomized clinical trialof Chinese patent medicine for the secondary prevention of myocardial infarction, and built the methods and key technology of evidence-based evaluation on Chinese medicine. He opened up the secondary exploitation field of Chinese patent medicine, which cultureda large group of big-market drugs and promote the technological upgrading of Chinese Medicine Industry.
He has won seven national science and technology awards and more than 20 provincial and ministerial scientific and technological progress awards. He has been delivered more than 200 papers. He has cultivated more than 180 post-doctoral students and postgraduates.
 
 
 
 
 
打印
分享到: 微信 更多
农工党中央网站版权与免责声明:
① 凡本网注明“来源:农工党中央”的所有文字、图片和音视频稿件,版权均属农工党中央和农工党中央网站所有,任何媒体、网站或个人如有需要链接转载或其它 方式调用者,请注明摘自“农工党中央网站”或相关字样。
② 凡本网未注明“来源:农工党中央”的所有文字、图片和音视频等稿件均为转载稿,本网转载仅为提供更多信息和促进交流之目的,不代表同意其观点或证实其内容的真实性,不代表本站观点,仅供参考,我们不作任何承诺保证,不承担任何的责任。如其他媒体、网站或个人从本网下载使用,必须保留本网注明的"稿件来源",并自负版权等法律责任。如擅自篡改为"来源:农工党中央",本网将依法追究责任。
③ 如因作品内容、版权和其它问题需要同本网联系的,请在30日内进行。※